Casirivimab/imdevimab vs placebo
Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower infection with SARS‐CoV‐2 within 6 monthsa compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 0.01 [0, 0.14]1 study · 825 participantsLow